Josh Lipton is CNBC's technology correspondent, working from CNBC's San Francisco bureau, CNBC@1Market. Lipton joined CNBC in January 2013 as an on-air markets reporter located at CNBC Global Headquarters in Englewood Cliffs, N.J.
Previously, Lipton was the markets editor for Bloomberg Television where he was responsible for all markets coverage, working with Bloomberg's team to develop reports on stocks, bonds, currencies and commodities. He also appeared weekdays on "In the Loop with Betty Liu."
Prior to joining Bloomberg in June 2011, Lipton was a staff writer at Minyanville, an online financial news source, where he covered the capital markets. He also served as a staff writer for Forbes, where he reported on finance and investing and contributed stock recommendations and investigative feature stories. Lipton appeared weekly on "Forbes on Fox," the internationally syndicated television news program focused on economics and the financial markets.
Lipton's stories have appeared in Rolling Stone, The Wall Street Journal, and The American Lawyer, among other publications.
He holds a Bachelor of Arts degree from Colgate University and a master's from both The London School of Economics and Columbia University Graduate School of Journalism.
Follow Josh Lipton on Twitter @CNBCJosh.
CNBC's Josh Lipton reports the latest on nootropics, a biohacking trend tech workers are turning to for peak mental and physical performance.
In Silicon Valley, entrepreneurs and engineers try to "hack" their brains and bodies with fasting, supplements and smart drugs called nootropics.
CNBC's Josh Lipton reports on "biohacking" in Silicon Valley where people are trying to improve their lives through new supplements.
Amazon continues to be the dominant force in the cloud services war, but Google and Microsoft are making progress.